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1 ZUSAMMENFASSUNG 
 
Pseudomonas aeruginosa ist ein Gram-negatives Pathogen, das bei Patienten mit defekten 
Abwehrbarrieren schwere Infektionen verursacht. Wegen der Entwicklung von Stämmen, die gegen 
mehrere Antibiotika resistent sind, ist eine neue antiinfektive Strategie dringend nötig. Das Target 
die intrabakterielle kommunication, genannt Quorum Sensing (QS), scheint der ideale Ansatz. 
Dieses System koordiniert die Pseudomonas-Virulenz und seine Blockade unterdrückt effizient die 
bakterielle Pathogenität, ohne das Wachstum zu beeinflussen. Unter den verschiedenen QS 
Systemen wurde das pqs System aufgrund seiner einzigartigen Präsenz in P. aeruginosa als Ziel 
ausgewählt. 
Die zwei biosynthetischen Proteine PqsD und PqsBC, die für die Signalmolekülproduktion 
notwendig sind, und der Transkriptionsregulator MvfR (PqsR) wurden als potentielle Target für die 
Blockierung dieses Systems ausgewählt. Zwei verschiedene Strategien wurden verwendet, um neue 
PqsD-Inhibitoren zu entwerfen und zu synthetisieren, die sowohl in zellfreien als auch ganzen 
Zelltests aktiv waren. Weiterhin wurden alle bei der Signalmoleküle-Biosynthese produzierten 
Substanzen nach der Inkubation mit PqsBC-Inhibitoren oder MvfR-Antagonisten untersucht. 
Interessanterweise wurde ein einzigartiges Profil für jede Klasse von QS-Inhibitoren beobachtet. 
Am Ende half diese Studie beim Verstehen, dass MvfR das beste Target ist, um das pqs-System zu 
blockieren und ein effizienteste Ergebnis zu erzielen. 
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2 ABSTRACT 
 
Pseudomonas aeruginosa is a Gram-negative pathogen which causes severe infections in 
patients with compromised defense barriers. Because of the development of more and more resistant 
strains to multiple antibiotics, a new strategy for treating these bacterial infections is highly 
required. Targeting a type of cell-to-cell communication, called Quorum Sensing (QS), seems to be 
the ideal approach. This system is needed for coordinating Pseudomonas virulence and its blockage 
efficiently suppresses the bacterial pathogenicity without affecting growth. Among the different 
cell-to-cell communication systems, the pqs system was chosen as target because of its unique 
presence in P. aeruginosa.  
Three proteins were selected as potential targets for blocking this system, such as the two 
biosynthetic proteins PqsD and PqsBC, necessary for signal molecule production, and the 
transcriptional regulator MvfR (PqsR). Two different strategies were employed for designing and 
synthesizing novel PqsD inhibitors which revealed to be active both in cell-free and whole cell 
assays. Furthermore, the production of all main compounds produced during signal molecule 
biosynthesis after incubation with PqsBC inhibitors or MvfR antagonists was investigated. 
Interestingly, a unique profile for each class of QS inhibitor was observed. In the end, this study 
helps in understanding that MvfR would be the best target to inhibit for blocking the pqs system and 
having the most efficient result. 
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7 INTRODUCTION 
7.1 Brief history of antibiotic research 
The discovery of penicillin, the first antibacterial agent against Staphylococcus and 
Streptococcus, by Fleming in 1928 (Fleming, 1929) was a milestone in the history of medicine. 
From that year, the "Golden Age" of antibiotic research started and, until the late 1960s, the 
scientific community identified new classes of antibiotics with different spectra width capable to 
block all the main targets of bacterial metabolism. However, the misuse of these precious tools 
during the XX century in clinics and agriculture induced a natural selection in the bacterial 
community of resistant strains towards these drugs (Fig. 1) (Brown, Wright, 2016). 
 
Fig. 1 Timeline of the first employment of the antibacterial agents (above the timeline) and the first assessment of 
resistance towards the drug (below the timeline) (Clatworthy et al., 2007). 
Actually, the number of new clinical isolates with acquired antibiotic resistance increased 
years after years (Schäberle, Hack, 2014). Because of their spread in clinics and environment, and 
the difficulties in developing new antibacterial drugs in last three decades, the treatment of 
infections caused by bacteria resistant towards more than three antibiotics, named multidrug 
resistant (MDR) (Obritsch et al., 2004), has become increasingly complicated. Among the 
prokaryotes, the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) 
(Pendleton et al., 2013) are the most dangerous ones because of their capability to become MDR. 
Actually, around 26000 patients die each year only in EU from MDR bacterial infections and the 
estimated costs for treating patients affected by these superbugs are at least 1.5 bilion € per year 
(ECDC/EMEA Joint Working Group, 2009). Consequently, an urgent need of new anti-infectives is 
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present for avoiding a threatening scenario in which mankind will not have any shield as protection 
against MDR bacteria. 
 
 
7.2 Pseudomonas aeruginosa 
7.2.1 Clinical importance 
Pseudomonas aeruginosa (P. a.) is a facultative anaerobe Gram-negative bacterium 
(Pendleton et al., 2013) belonging to the family of the Pseudomonaceae. It is an opportunistic 
pathogen which is the cause of severe hospital-acquired infections (Lister et al, 2009). It affects 
mainly patients with compromised immune system, for example people with burned wounds 
(Tredget et al., 2004), suffering from cystic fibrosis (Gómez, Prince, 2007) or infected by HIV (Busi 
Rizzi et al., 2006). The eradication of P. a. is becoming more and more difficult because of the wide 
occurrence of MDR strains. For example, in the period 1993 – 2002 an increase from 4 % to 14 % 
(Obritsch et al., 2004) causing a mortality of 39 % among the infected patients from 1998 to 2001 
(Kang et al., 2003). This pathogen showed to be less sensitive to ciprofloxacin, imipenem, 
tobramycin and aztreonam (Obritsch et al., 2004) which are the first-line antipseudomonal 
antibiotics (Hill et al., 2005). The resistance towards these drugs was acquired over time by this 
bacterium through two main mechanisms, such as imported or chromosomally encoded (Lister et al, 
2009). The first type is based on plasmid transfer among bacteria carrying genes for expressing β-
lactamases (Livermore, Woodford, 2006) or aminoglycosides modifying enzymes (Hancock, 1998). 
The second mechanism occurs by mutation in the bacterial genome causing a target mutation, as in 
the gyrase gene transferring quinolone resistance, or a different expression of transport proteins in 
the bacterial membranes, for example upregulation of efflux pumps and downregulation of porines 
(Lister et al, 2009; Hancock, 1998).  
In both cases, the resistance was acquired by the pathogen because the antibiotic affected 
bacterial growth and, for survival, the bacterial community developed the tools for reducing the 
compounds’ activity. Consequently, a different approach should be considered for blocking P. a. 
infections without interfering with the life cycle of the pathogen.  
Recently, a potential efficient strategy has been identified through the blockage of the 
production and/or the expression of virulence factors necessary for acute and/or chronic infection 
without killing the pathogen, the so-called “Anti-virulence strategy” (Maura et al., 2016; Wagner et 
al., 2016; Clatworthy et al., 2007). One important advantage of this approach would be the 
potentially low rate of resistance because the survival of the bacterium will not be affected by the 
active agent itself. Consequently, the bacterial community would not have the pressure to develop 
tools for inactivating the target compounds (Allen et al., 2014; Rasko, Sperandio, 2010). 
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7.2.2 Virulence factors production during infection 
Acute P. a. infections follow three main steps, adhesion, invasion and systemic 
dissemination, in which the pathogen attacks the host using several cell-associated and extracellular 
virulence factors (Todar, 2009). 
After damage of the host natural barriers, as the skin, or reduced efficiency of the immune 
system, as in patients affected by AIDS, the bacterium has the possibility to adhere on the epithelial 
cells using sugar binding proteins as fimbriae (known also as polar type IV pili) (Persat et al., 2015), 
flagella (Feldman et al., 1998) and LecA and LecB lectins (Strateva, Mitov, 2011). Then, the 
pathogen starts producing the elastases LasA and LasB which hydrolase elastine, an essential 
protein of the connective tissue (Galloway, 1991), and surfactant peptides, important tools of the 
lung innate immunity (Mariencheck et al., 2002). In addition, it expresses alkaline protease 
necessary for the degradation of complement components and inflammatory cytokines (Laarman et 
al., 2012). Furthermore, P. a. enhances the production of rhamnolipids and hemolytic phospholipase 
C which are responsible of the dissolution and hydrolization of phospholipids, especially 
phosphatidylcoline, present in the eukaryotic membranes and lung surfactants (Stateva, Mitov, 
2011). Moreover, the bacterium synthesizes the redox toxin pyocyanin which interferes with 
multiple mammalian cell functions (Stateva, Mitov, 2011) as the cell respiration, and several 
siderophores, for example pyochelin and pyoverdin, important for iron-uptake and, consequently, 
bacterial growth (Hoergy et al., 2014). After colonizing and growing in the infection site, P. a. can 
disseminate in the whole body through the blood stream using the same virulence factors employed 
in the adhesion and invasion steps (Stateva, Mitov, 2011). In addition, the exposition of lipid A, the 
lipophilic moiety of the lipopolisaccarides present in the outer membrane, to the blood is the main 
cause of the Gram-negative septicemia (Stateva, Mitov, 2011).  
Moreover, the pathogen can start building biofilms in the colonized sites, which are 
composed of a complex mixture of exopolisaccarides, rhamnolipids, extracellular DNA and proteins 
(Flemming, Wingender, 2010), causing the establishment of a chronic infection (Wagner et al., 
2016). This heterogeneous structure is formed around the cells for improved adhesion and 
stabilization on host tissues, and for creating a physical barrier to several biocides, as reactive 
chemicals (bleach or superoxides), the immune system, UV light and antimicrobial agents (Hall-
Stoodley et al., 2004). Furthermore, the bacterial community is not homogeneous in the biofilm. 
Actually, the cells present in the middle of this heterogeneous matrix are less metabolically active 
compared to the ones located on the surface because of a lower access to oxygen. So, these bacteria 
become dormant. Taking into consideration that the antibiotics block metabolic pathways, these 
drugs can kill only pathogens with an active metabolism, such as the cells on the surface, and not the 
one inside the biofilm which are, then, called "persisters" (Walter III et al., 2003). When the 
concentration of the antibiotic reaches sub-inhibitory levels, the persister cells can switch their 
metabolic pathways on and repopulate the tissue. Consequently, the presence of dormant cells leads 
to recalcitrant infections very difficult to eradicate (Lewis, 2010). 
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7.2.3 Quorum Sensing 
The behavior of P. a. in acute and chronic infections is controlled by a complex regulatory 
system called Quorum Sensing (QS) (Wagner et al., 2016). 
The QS is a cell-to-cell communication system used by both Gram-positive and Gram-
negative in which the bacteria synthesize and release small molecules, so called auto-inducers (AIs), 
depending on bacterial cell density and nutrient concentrations, for examples phosphate or iron. 
These molecular signals diffuse in the community and interact with their respective regulators for 
coordinating the expression of specific genes. Among these are the ones necessary for virulence 
factors and biofilm production, and for the synthesis of the signal molecules (Lee, Zhang, 2014).  
P. a. employs at least four different QS networks interconnected to each other, such as the 
las, rhl, iqs and pqs (Fig. 2). These systems employ transcriptional regulators, respectively LasR, 
RhlR, IqsR and PqsR (also called Multiple virulence factor Regulator, MvfR), which, after binding 
their specific AIs, activate the expression of selected genes connected to virulence (Lee, Zhang, 
2014). 
 
Fig. 2 Quorum Sensing networks in Pseudomonas aeruginosa. Black line-arrows: activation. Red line-dots: 
inhibition. (Edited picture from Lee, Zhang, 2014; Maura et al., 2016). 
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The las system makes use N-butanoyl-L-homoserinelactone (C4-HSL) as signal molecule 
and it induces the expression of LasA and LasB elastases, alkaline protease, MvfR, RhlR, IqsR and 
the cognate synthatase LasI. The rhl system employs a molecule of N-(3-oxododecanoyl)-L-
homoserinelactone (3-oxo-C12-HSL) as AI and it favors the production of rhamnolipids, LasB 
elastase, pyocyanin, hydrogen cyanide, the related signal molecule biosynthetic protein RhlI and the 
downregulation of mvfR (Lee, Zhang, 2014). The most recent discovered iqs employs 2-(2-
hydroxyphenyl)-thiazole-4-carbaldehyde (IQS) and it positively regulates the pqs system, but further 
investigations are necessary for better understanding of its role in P. a. infections (Lee et al., 2013). 
The pqs system utilizes Pseudomonas Quinolone Signal (PQS) as QS molecule and it activates the 
synthesis of pyocyanin, hydrogen cyanide, LecA lectin, the enzymes needed for PQS biosynthesis, 
the expression of RhlR (Lee, Zhang, 2014) and LasR (Maura et al., 2016). In addition, the las, rhl 
and pqs systems coordinate biofilm formation (Christensen et al., 2007; Hurley et al., 2012; Smith, 
Iglewski, 2003). 
 
7.2.4 Proof of Concept: Quorum Sensing inhibition as anti-virulence strategy 
Based on the importance of QS in regulating virulence factors and biofilm formation, the 
scientific community considered these cell-to-cell communication systems as potential drug targets. 
Actually, in vivo studies demonstrated that strains lacking in the expression of the transcriptional 
regulators and/or of the AI biosynthetic pathways provoked a lower mortality of mice compared to 
the animals treated with the wild-type P. a.. So, these findings were the proof that the QS is a 
valuable target for the anti-virulence strategy (Christensen et al., 2007; Rumbaugh et al., 1999; Xiao 
et al., 2006a). Consequently, three possible approaches could be considered for the development of 
Quorum Sensing Inhibitors (QSIs), such as inhibition of the AI syntheses, inactivation of the signal 
molecules and interference with the transcriptional regulators (Wagner et al., 2016). 
 
 
7.3 The pqs system 
Several Gram-negative bacteria, for example Vibrio fischeri and Pantoea sterwatii, make use 
of signal molecules belonging to the class of homoserinelactones (HSL) for their QS systems as P. 
a. (Fugua et al., 2001; Miller, Bassler, 2001). On the contrary, quinolone-like quorum sensors are 
employed only by P. a. (Pesci et al., 1999) and some species of Burkholderia (Vial et al., 2008; 
Diggle et al., 2006). Taking into consideration that P. a. causes severe infections in patients with 
compromised barriers and immune system, a selective anti-Pseudomonas therapy would be 
preferable. Consequently, the ideal cell-to-cell communication system to be targeted would be the 
pqs as it would be possible to develop selective inhibitors without having side effects on other 
bacteria, as the Gram-negative Escherichia coli which lives in symbiosis with us in our gut (Zhang 
et al., 2015).  
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7.3.1 The pqs-related small molecules and their biosynthesis 
As previously mentioned, the pqs system employs as signal molecules the quinolone PQS 
(Pesci et al., 1999) and its precursor HHQ (Xiao et al., 2006a). Their biosynthesis require several 
enzymes which are expressed by the polycistronic operon pqsABCDE (Gallagher et al., 2002; Déziel 
et al., 2004; McGrath et al., 2004), and pqsH (Gallagher et al., 2002) (Fig. 3). 
 
Fig. 3 Current model of the biosynthetic pathway of MvfR-related small molecules. AA: anthranilic acid. CoASH: 
Coenzyme A. A-CoA: anthraniloyl-CoA. M-CoA: malonyl-CoA. 2-ABA-CoA: 2’-aminobenzoylacetyl-CoA. 2-ABA: 
2’-aminobenzoylacetate. DHQ: dihydroxyquinoline. 2-AA: 2’-aminoacetophenone. 2-HABA: 2’-
hydroxylaminobenzoylacetate. HHQ: 4-hydroxy-2-heptylquinoline. HQNO: 4-hydroxy-2-heptylquinoline-N-oxide. 
PQS: Pseudomonas Quinolone Signal. 
The production of the signal molecule starts from a molecule of anthranilic acid (AA) which 
is transformed into anthraniloyl-CoA (A-CoA) by the Coenzyme A (CoA) ligase PqsA (Coleman et 
al., 2008). Then, the thioester A-CoA is converted by PqsD into 2’-aminobenzoylacetate-CoA (2-
ABA-CoA) after reacting with a molecule of malonyl-CoA (M-CoA) (Dulcey et al., 2013). So, the 
thioesterase PqsE cleaves the thioester bond of 2-ABA-CoA for getting the reactive intermediate 2’-
aminobenzoylacetate (2-ABA) (Drees, Fetzner, 2015) which is transformed into 4-hydroxy-2-
heptylquinoline (HHQ) after condensation with a molecule of octanoyl-CoA by the hetero-dimer 
PqsBC (Dulcey et al., 2013). Finally, HHQ is oxidized by the flavin monooxygenase PqsH into PQS 
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(Schertzer et al., 2010). Moreover, 2-ABA-CoA and 2-ABA are important intermediates for the 
biosynthesis of other compounds important for P. a. infection. Actually, both molecules can undergo 
to an intramolecular cyclization resulting in the formation of dihydroxyquinoline (DHQ). In 
addition, 2-ABA can be decarboxylated and transformed into the volatile molecule 2’-
aminoacetophenone (2-AA). Finally, 2-ABA could be oxidized by PqsL into the hydroxylamine 
analogue which would be converted into 4-hydroxy-2-heptyl-quinoline-N-oxide (HQNO) by PqsBC 
(Dulcey et al., 2013; Déziel et al., 2004). 
Even if a deep analysis of the biosynthetic products of the pqs system revealed that P. a. 
produces more than 50 pqs-related small molecules (Lépine et al., 2004), the bacterium synthesizes 
mainly PQS, HHQ, HQNO, DHQ and 2-AA and their role in Pseudomonas infections was 
elucidated. PQS and HHQ behave as signal molecules of the pqs system binding the transcriptional 
regulator MvfR, but with different potency. Actually, the dihydroxyl-quinoline is 100 times more 
potent than the monohydroxyl-analogue (Xiao et al., 2006a; Diggle et al., 2007). Nonetheless, the 
analysis of these alkyl-quinolines (AQs) in in vivo studies, such as clinical cases and animal 
experiments, revealed that the amount of HHQ is higher than PQS in the infection sites (Que et al., 
2011; Xiao et al., 2006a). It is plausible to assume that the pathogen produces HHQ and exports it in 
the extracellular space by the efflux pump MexEF-OprN (Lamarche, Déziel, 2011). Consequently, 
the molecule permeates in the bacteria, is oxidized by PqsH into PQS and finally transported outside 
the cells through membrane vesicles traffic (Mashburn, Whiteley, 2005; Déziel et al., 2004). 
Moreover, because of the presence of the 3,4-dihydroxyl moiety, PQS is important in iron 
homeostasis based on its capability to chelate ferric ions and favoring its transport into the cell 
(Diggle et al., 2007). Furthermore, PQS, but not HHQ, is essential for full production of the redox-
toxin pyocyanin (Xiao et al., 2006a). HQNO is necessary for coordinating the autolysis of the 
prokaryotic cells for the consequent release of DNA in the extracellular space, a fundamental 
component of the bacterial biofilm (Hazan et al., 2016). Furthermore, the N-oxide quinoline inhibits 
the proliferation of Gram-positive bacteria, as Staphylococcus aureus, and, consequently, it helps P. 
a. to colonize the environmental niche of infection (Déziel et al., 2004; Machan et al., 1992). DHQ 
is used by the pathogen as toxin against epithelial cells for inhibiting their cellular growth (Zhang et 
al., 2008) and is necessary for Pseudomonas pathogenicity, as pyocyanin production (Gruber et al., 
2016). The small volatile molecule 2-AA is fundamental for the transition from acute to chronic 
infection favoring the formation of persister cells within the bacterial community (Kesarwani et al., 
2011; Que et al., 2013). 
 
7.3.2 Targeting the biosynthetic pathway 
Blocking the biosynthesis of the signal molecules has been shown to be an efficient strategy 
for reducing PQS and HHQ production in P. a. cultures and, consequently, reduce its virulence 
(Wagner et al., 2016). Among the enzymes necessary for the synthesis of the pqs-related small 
molecules, the two oxidases PqsH and PqsL have not been considered attractive targets as the 
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respective P. a. mutants would be still capable to synthesize the QS signal molecules (Lépine et al., 
2004; Déziel et al., 2004; Gallagher et al., 2002). Furthermore, even if PqsE is important for the 
cleavage of the thioester bond of 2-ABA-CoA for releasing 2-ABA, its function in the biosynthetic 
pathway can be taken over by the non-specific thioesterase TesB as P. a. pqsE mutant still produce 
HHQ and PQS (Drees, Fetzner, 2015). So, the enzymes to target for blocking the AQs production 
would be PqsA, PqsD and the dimer PqsBC as their P. a. mutants were not able to generate any 
signal molecules (Zhang et al., 2008). As the crystal structure of PqsA has not been elucidated until 
now, the most attractive proteins for designing QSIs would be PqsD and PqsBC based on the 
important information obtained from the X-ray data (Bera et al., 2009; Drees et al., 2016). 
Both PqsD and PqsBC belong to the β-ketoacyl-ACP synthase III (FabH) family, a class of 
condensing enzymes which employ substrates conjugated to CoA by thioester bonds (Bera et al., 
2009). Another characteristic of FabH-like proteins is the presence of the catalytic triad Cys-His-
Asp which is fully present in PqsD, while partially in PqsC as Cys-His diad and completely absent 
in PqsB (Bera et al., 2009; Drees et al., 2016). 
PqsD is constituted by 337 aminoacids and it exists as a homo-dimer in the bacterial cytosol 
(Bera et al., 2009). This protein catalyzes the conversion of A-CoA into 2-ABA-CoA through two 
steps: 1) the anthranilate is transferred onto Cys112 through trans-thioesterification releasing one 
CoA molecule; 2) the complex anthranilate-PqsD reacts with M-CoA through a nucleophilic 
substitution leading to the loss of a CO2 molecule and release of 2-ABA-CoA (Bera et al., 2009; 
Dulcey et al., 2013). Furthermore, through a similar mechanism, PqsD can catalyze in vitro the 
conversion of A-CoA into HHQ using a molecule of β-ketodecanoic acid (Pistorius et al., 2011). 
Several strategies were used for designing PqsD inhibitors, such as ligand-based and 
similarity-guided approaches (Wagner et al., 2016). The first method was based on the transition 
state of the first enzymatic step in which there is the formation a tetrahedral intermediate. Starting 
from substrate analogues followed by structure simplification, the PqsD inhibitor I was obtained 
highly active in reducing HHQ production both in vitro and in cellulo assays (Fig. 4) (Storz et al., 
2012). 
 
Fig. 4 Ligand-based design concept based on the transition state of the first PqsD enzymatic reaction. (Edited figure 
from Storz et al., 2012). 
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The second approach started considering the similarities between the PqsD and FabH 
families and from known inhibitors of the latter class of proteins novel inhibitors of the bacterial 
enzyme were designed capable to reduce efficiently HHQ and PQS production in vitro (Hinsberger 
et al., 2014; Weidel et al., 2013). These results demonstrated that the inhibition of PqsD is a 
valuable tool for reducing QS molecules production and, consequently, further investigations were 
required for optimizing the lead QSI and for identifying novel inhibitors.  
PqsBC is a hetero-dimer formed by the subunit B and C consisting of 283 and 350 
aminoacids, respectively. While the role of PqsB is still unclear, PqsC is necessary for the 
condensation of 2-ABA with an octanoyl chain through a three steps-reaction: 1) the octanoyl-CoA 
is transferred onto Cys129 of the catalytic pocket through a trans-thioesterification reaction; 2) 2-
ABA loses a CO2 molecule forming a reactive enolate; 3) the carbanion attacks the electrophilic 
thioester for getting an intermediate which spontaneously cyclizes into HHQ (Drees et al., 2016).  
Considering that the enzymatic mechanism was only recently elucidated, only few 
compounds could be developed against this target until today (Starkey et al., 2014). So, more efforts 
should be put in studying the effects of PqsBC inhibitors on the pqs system. Based on the findings 
obtained, the scientific community would have additional information for understanding the impact 
of these QSIs on the pqs biosynthetic machinery and, consequently, further elucidating its 
functionality. 
 
7.3.3 The transcriptional regulator MvfR 
As previously described, the pqs system makes use of the transcriptional regulator MvfR 
which belongs to the family of LysR-type transcriptional regulators (LTTR) (Xiao et al., 2006a). 
This protein is constituted by 332 aminoacids and it has a DNA-binding domain at the N-terminus 
used for binding the promotor of the genes to be expressed, and a ligand-binding domain at the C-
terminus in which the signal molecule interacts with the regulator (Schell, 1993). MvfR is a 
membrane-associated protein that is mainly expressed in the late exponential phase of bacterial 
growth (Cao et al., 2001). After binding the signal molecule, the protein forms a dimer or a tetramer 
and, then, strongly binds the promoter regions of the genes under its regulation activating their 
transcription (Cao et al., 2001; Xiao et al., 2006b; Kirsch et al., unpublished data). Subsequently, 
when the bacterial culture enters in stationary phase, the MvfR is translocated in the extracellular 
space and cleaved by a protease which causes the inactivation of the transcriptional regulator (Cao et 
al., 2001).  
 
7.3.4 Targeting the transcriptional regulator 
The transcriptional functionality of MvfR can be positively or negatively modulated based 
on the interactions established by small molecules in the ligand-binding pocket of the protein. For 
decreasing the P. a. pathogenicity the ideal approach is reducing the protein activity through the 
administration of antagonists (Wagner et al., 2016). The scientific community developed several 
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classes of MvfR antagonists applying different strategies, such as those based on the scaffold of the 
natural ligands (Lu et al., 2014; Ilangonav et al., 2013), or guided by the analysis of small fragments 
binding to the protein (Klein et al., 2012; Zender et al., unpublished data), or highthroughput 
screening (Starkey et al., 2014). The results obtained have in common that the compounds were 
capable to reduce pqs transcription, signal molecule biosynthesis, virulence factors production, like 
pyocyanin and rhamnolipids, and biofilm formation (Lu et al., 2014; Ilangonav et al., 2013; Klein et 
al., 2012; Zender et al., unpublished data; Starkey et al., 2014). These findings highlighted the 
efficiency of this approach in inhibiting the pqs system and, consequently, P. a. pathogenicity. 
However, a complete analysis of the mvfR-related small molecules biosynthesis after the treatment 
of the bacteria with MvfR antagonists was not performed. Actually, a deeper evaluation of their 
effects on 2-AA, DHQ, HQNO, HHQ and PQS production would help in better understanding the 
biosynthetic machinery and, in addition, indicating the optimal dosage of QSI to administer for 
treating P. a. infections. 
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8 AIM OF THE THESIS 
 
Among the human pathogens, the opportunistic bacterium P. a. has been considered to be a 
serious health problem because of the difficulties in eradicating this prokaryote through antibiotic 
therapies due to its resistance mechanisms. Actually, after circa a century of antibacterial drugs 
usage, the natural selection let the bacteria become less sensitive towards these compounds which 
consequently have lost their therapeutic efficiency. Among the novel strategies proposed for treating 
P. a. infections, blocking the pqs cell-to-cell communication system was proven to successfully 
reduce the bacterial virulence blocking both the key enzymes of the signal molecule biosynthesis 
PqsD and PqsBC, and the transcriptional regulator MvfR. 
The first goal of the thesis was to optimize the activity of the PqsD inhibitor I discovered by 
Storz and coworkers in the cell-free assay and studying the Structure-Activity Relationship (SAR) of 
this class of QSIs. Furthermore, the effect of the substituents on the time-dependent onset of 
inhibition was investigated in vitro. In addition, the efficacy of the developed QSIs in reducing 
signal molecule production was assessed in the whole-cell assay and a correlation of the results 
between in vitro and in cellulo settings was attempted.  
Based on the promising results got from the application of the similarity-guided approach, 
the second aim of the thesis was to examine enzymes having common features and similar function 
with PqsD in nature. Subsequently, the substrates of this protein were evaluated in the cell-free 
assay and, through chemical modifications of the scaffold, an SAR was evaluated. Furthermore, the 
binding mode of this class of PqsD inhibitors was analyzed using Surface Plasmon Resonance 
(SPR). Then, the activity of these QSIs was examined in P. a. cultures. 
The third aim of the thesis was to investigate the effects of PqsBC inhibitors and MvfR 
antagonists on pqs-related small molecules production after incubation with P. a. strains for 
understanding more deeply the signal molecules biosynthetic machinery. Moreover, the influence of 
these QSIs on the persistence phenotype was evaluated. 
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9.3 Elucidation of the profile of MvfR-regulated small molecules in 
Pseudomonas aeruginosa after Quorum Sensing Inhibitors treatment 
 
Introduction 
Pseudomonas aeruginosa is a ubiquitous Gram-negative bacterium able to cause severe chronic 
infections in immuno-compromised patients, for example in people affected by cystic fibrosis 
(Gómez, Prince, 2007) or thermally injured individuals (Tredget et al., 2004). The eradication of this 
pathogen with antibiotic treatments is becoming more and more difficult because of its intrinsic and 
acquired resistance (Hancock, Speert, 2000; Aloush et al., 2006) and tolerance (Mulcahy et al., 
2010) toward these drugs. A new promising strategy for treating Pseudomonas aeruginosa 
infections is blocking its pathogenicity without killing the bacteria targeting a cell-to-cell 
communication system called Quorum Sensing (QS) (Hurley et al., 2012). 
This bacterium employs four interconnected QS systems, namely las, iqs, pqs, and rhl that regulate 
the expression of several toxins needed for adjusting its metabolism and virulence during the course 
of infection (Lee, Zhang, 2015). The pqs QS system is selectively expressed by P. aeruginosa and 
utilizes the signal molecule Pseudomonas Quinolone Signal (PQS) and its precursor 4-hydroxy-2-
heptylquinoline (HHQ) for activating the transcriptional regulator MvfR (Multiple Virulence Factor 
Regulator), also called PqsR. This protein induces the production of different toxins, such as lectins, 
pyocyanin, and hydrogen cyanide. It also regulates the expression of enzymes needed for the 
biosynthesis of its natural ligands encoded by the pqsABCDE operon (Xiao et al., 2006) and has 
been shown to be essential for persister cells development (Que et al., 2013).  
Briefly, the synthesis of HHQ and PQS starts with the conversion of anthranilic acid (AA) into its 
Coenzyme A (CoA) thioester derivative by the action of CoA-ligase PqsA. The activated molecule 
is then condensed with malonyl-CoA by PqsD leading to the formation of 2'-aminobenzoylacetyl-
CoA (2-ABA-CoA), which is subsequently hydrolyzed by the thioesterase PqsE into 2'-
aminobenzoylacetate (2-ABA) (Dulcey et al., 2013; Drees, Fetzner, 2015). This reactive 
intermediate is transformed into HHQ by the heterodimer PqsBC bearing an octanoyl chain (Dulcey 
et al., 2013). Finally, PqsH oxidizes HHQ into PQS (Schertzer, et al., 2010) (Fig. 1). 
Furthermore, 2-ABA-CoA and 2-ABA are intermediates for the biosynthesis of other important 
metabolites. Actually, both compounds can cyclize leading to the formation of dihydroxyquinoline 
(DHQ), which has been shown to be fundamental in P. aeruginosa pathogenicity (Gruber et al., 
2016), and in reducing the growth of epithelial cells (Zhang et al., 2008). Moreover, after 
decarboxylation, 2-ABA is converted into 2'-aminoacetophenone (2-AA), an important signal 
molecule that coordinates the transition from acute to chronic infection and the development of 
persister cells (Kesarwani et al., 2011; Que et al., 2013). In addition, 2-ABA could be converted into 
its hydoxylamine form by the oxidase PqsL and, then, transformed into 4-hydroxy-2-
heptylquinoline-N-oxide (HQNO) by the complex octanoyl-PqsBC (Dulcey et al., 2013). HQNO is 
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essential for biofilm formation because it favors extracellular DNA release by programmed cell 
lyses of the bacteria (Hazan et al., 2016). 
 
Figure 1 Current model of the biosynthetic pathway of MvfR-related small molecules. AA: anthranilic acid. CoASH: 
Coenzyme A. MCoA: malonyl-CoA. 2-ABA-CoA: 2'-aminobenzoylacetyl-CoA. 2-ABA: 2'-aminobenzoylacetate. DHQ: 
dihydroxyquinoline. 2-AA: 2'-aminoacetophenone. 2-HABA: 2'-hydroxylaminobenzoylacetate. HHQ: 4-hydroxy-2-
heptylquinoline. HQNO: 4-hydroxy-2-heptylquinoline-N-oxide. PQS: Pseudomonas Quinolone Signal. 
Among the potential targets for blocking the pqs system, we herein discuss the transcriptional 
regulator MvfR and the biosynthetic enzyme PqsBC. So far, a number of MvfR antagonists and 
PqsBC inhibitors has been developed that efficiently reduced HHQ and PQS production in P. 
aeruginosa (Zender et al., 2013; Lu et al., 2014a; Starkey et al., 2014). The aim of this work was to 
gather detailed information about the effects of these QS Inhibitors (QSIs) on the production of 
MvfR-related small molecules including 2-AA, DHQ, HQNO, HHQ, and PQS. Furthermore, we 
monitored the expression of the pqs operon in a time-dependent manner upon treatment with the 
aforementioned QSIs. 
Among the QS molecules, 2-AA was proven to be important in the development of P. aeruginosa 
persister cells (Kesarwani et al., 2011; Que et al., 2013), which are metabolically inactive 
individuals within the bacterial population (Lewis, 2010). Due to their dormant state, antibiotic 
efficacy is severely impaired in this bacterial sub-group. Targeting persistence by blocking 2-AA 
production through QS inhibition was shown to be a promising strategy (Starkey et al., 2014). 
Consequently, an additional goal of the work was to quantify persister phenotype of P. aeruginosa 
after treatment with QSIs. 
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Material and Methods: 
Chemicals and growth media 
1, 2 and 3 were synthesized as described in literature (Rahme et al, 2012; Zender et al., in press; 
Storz et al., 2014). d4-HHQ was synthesized following the procedure of HHQ using d5-aniline (Lu et 
al., 2012). 4 and amitriptyline were purchased from ChemDiv (USA) and Alfa Aesar (Germany), 
respectively. 
Water (Th. Geyer, Germany), acetonitrile (VWR, Germany) methanol (Sigma-Aldrich, USA) and 
formic acid (Fluka, USA) were LC−MS grade and used for HPLC−MS/MS experiments. 
Yeast extract (Fluka, Germany), sodium chloride (VWR, Germany) and peptone from casein 
(Merck, Germany) were used for the preparation of Luria Bertani (LB) broth needed for performing 
the quantification experiments of pqs-related signal molecules. Ready-made mixture of LB broth 
(Fisher, USA) and Tryptic Soy Broth (TSB) 1% [w/v] (BD, USA) were used for pqsA-GFPASV and 
persister cells experiments. 
 
Bacterial strains 
P. aeruginosa PA14 and its isogenic transposon mutants pqsA, pqsC, pqsH and pqsE kindly 
provided by Susanne Häussler (Twincore, Hannover, Germany) were used in the experiments for the 
quantification of MvfR-related small molecules with and without QSIs. P. aeruginosa PA14, its 
isogenic pqsBC transposon mutant, and its mvfR single mutant were employed for performing 
persister cells assays. P. aeruginosa PA14 transformed with pAC37 carrying pqsA-GFPASV and 
gentamicin resistance cassette was used in pqsA expression experiments. The bacterial strains were 
maintained at −80°C in 25 % [v/v] glycerol stocks. 
 
MvfR-related small molecule quantification 
P. aeruginosa strains were cultivated as previously described (Maurer et al., 2013). After letting 
PA14 strains grow for 6 h in LB, an aliquot of bacterial culture was centrifuged for 10 min at 4835 x 
g and 25 °C using a Rotina 380R Centrifuge (Hettich, Germany). The supernatant was discarded, the 
pellet was resuspended in fresh LB, and the bacterial cells were spun down using the previous 
centrifugation settings. After repeating the wash step a second time, the OD600 of the washed cells 
was measured using a BioPhotometer plus Spectrophotometer (Eppendorf, Germany) in order to 
prepare a final bacterial suspension with OD600 = 0.02 in LB. Aliquots of 1.5 mL were added in each 
well of a 24-well Cellstar plate (Greiner Bio-One, Frickenhausen, Germany). 15 μL of 
dimethylsulfoxide (DMSO) or DMSO stock solutions of the target compound were added in each 
well. Triplicates of each condition were evaluated in every assay. The plates were incubated for 17 h 
at 37 °C with 75 % humidity and shaken at 200 rpm. The quantification of anthranilic acid 
derivatives was performed following a previously described protocol (Lépine et al., 2003) with 
slight modifications. 750 µL of culture from each well were diluted with 750 µL of Internal 
Standard (IS) stock solution in acetonitrile. The IS employed in experiments with PA14 wt and pqsC 
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mutant was d4-HHQ at a final concentration of 500 nM, while the experiments in PA14 pqsH mutant 
required amitriptyline as IS at a final concentration of 1 μM. After mixing the diluted cell culture for 
5 min, the mixture was spun down for 15 min at 18,620 x g and 15 °C using a Mikro 220R 
Centrifuge (Hettich, Germany). 1 mL of supernatant was transferred in glass vial and analyzed with 
the Accela HPLC system (Thermo Fisher Scientific, Germany) coupled to a triple quadrupole mass 
spectrometer TSQ Quantum Access Max (Thermo Fisher Scientific Germany) equipped with an 
HESI-II source. Separation was achieved by a Macherey-Nagel Nucleodur C18 Pyramid column 
(150×2 mm, 3 µm) heated at 40 °C. The mobile phase consisted of 10:90 MeOH:H2O for 0.5 min, 
followed by a linear gradient of 1.5 min for reaching 100 % MeOH, which was kept constant for 1 
min. Then, the initial eluents composition was pumped for 2 min. The flow rate employed was 600 
µL·min
-1
. A final concentration of 0.1 % formic acid was present in the eluents. Compounds were 
ionized using heated electrospray ionization (hESI) in positive ion mode with the following 
parameters: spray voltage: 3500 V; vaporizer temperature: 370 °C; sheath gas pressure (nitrogen): 
35 units; auxiliary gas pressure (nitrogen): 30 units; skimmer offset voltage: 0 V; capillary 
temperature: 270 °C. Selected reaction monitoring was used for detecting DHQ (161.971→115.979, 
collision energy: 28 V, tube lens: 95 V), 2-AA (136.016→91.048, collision energy: 24 V, tube lens: 
68 V), HHQ (244.050→158.944; collision energy: 31 V; tube lens: 100 V), HQNO 
(260.036→158.908; collision energy: 28 V; tube lens: 110 V), PQS (260.048→174.927; collision 
energy: 30 V; tube lens: 110 V), d4-HHQ (248.081→162.965; collision energy: 32 V; tube lens: 100 
V) and amitriptyline (278.061→232.932; collision energy: 16 V; tube lens: 90 V) employing a scan 
width of 0.010 m/z, a scan time of 0.100 s, and a peak width of 0.70. Calibration curves were 
prepared following the same protocol and using PA14 pqsA mutant as matrix without compounds 
and spiked with known concentrations of analytes and IS after the overnight growth. The assays 
were repeated at least three times. 
 
pqsA expression assay 
The assays were performed following the protocol previously published (Kesarwani et al., 2011) 
with few modifications. After let PA14 wt transformed with pAC37 grow overnight in LB with 60 
µg/mL of gentamicin, an aliquot of bacterial culture was centrifuged for 5 min at 8000g at 25 °C 
using a 5810R Centrifuge (Eppendorf, USA). The supernatant was discarded, the pellet was 
resuspended in fresh LB with the same antibiotic and the bacterial cells were spun down using the 
previous centrifugation settings. After repeating the wash step a second time, the OD600 of the 
washed cells was measured using a Spectronic Unicam Genesys 10 UV spectrophotometer (Thermo 
Fisher, USA) in order to prepare a final bacterial suspension with OD600 = 0.02 in LB with 60 
µg/mL of gentamicin. 100 µL of the prepared culture was poured in each well of a 96-well plate 
(Corning Inc. Corning, USA) and the compounds were added in triplicates. The final concentration 
of DMSO was 1% v/v. The plates were incubated at 37°C under static condition in Infinite F200 
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plate reader (Tecan Group Ltd, Männedorf, Switzerland) monitoring GFP fluorescence (λex = 485 
nm; λem = 535 nm) and OD600 every 15 min. The assays were repeated at least three times.  
 
Persister cells assay 
The effects of QSIs on persistence were evaluated following the published protocol (Starkey et al., 
2014) with some modifications. After streaking the bacteria on LB agar and overnight incubation at 
37 °C, one colony was dispersed in 5 mL of LB and the bacteria were grown at 37 °C up to OD600 = 
0.5. 30 µL of the culture were transferred into glass tubes with 5 mL of TSB 1 % [w/v] and 
incubated overnight at 37°C under shaking condition. Then, an aliquot of P. aeruginosa culture was 
centrifuged for 5 min at 8,000 x g and 25 °C using a 5810R Centrifuge (Eppendorf, USA). The 
supernatant was discarded, the pellet was resuspended in fresh LB, and the bacterial cells were spun 
down using the previous centrifugation settings. After repeating the wash step a second time, the 
OD600 of the washed cells was measured using a Spectronic Unicam Genesys 10 UV 
spectrophotometer (Thermo Fisher, USA) in order to prepare a final bacterial suspension with OD600 
= 0.02 in 5 mL of TSB 1% [w/v] in each glass tube. The target compounds were added in the tubes 
and the final concentration of DMSO was 0.5 % [v/v]. The bacterial suspension was incubated at 37 
°C under shaking condition for 4 h. An aliquot of 100 µL of culture from each tube was used for 
dilution plating on LB agar plates and colony forming units (CFU) quantification (normalizers). 50 
µL of meropenem 1 mg/mL were added in each tube and the cultures were incubated at 37 °C for 24 
h under shaking condition. Aliquots of 600 µL of bacterial suspension were utilized for dilution 
plating on LB agar plates and CFU quantification (persisters). The survival fractions were calculated 
as the ratio of normalizers over persisters. Triplicates per each condition were employed in each 
assay and the experiments were repeated at least three times.  
 
 
Results and Discussion 
The QSIs evaluated in this study were the two MvfR antagonists 1 (Starkey et al., 2014) and 2 
(Zender et al., unpublished results), and the two PqsBC inhibitors 4 (Starkey et al., 2014) and 3 
(unpublished results) shown in Figure 2. As previously published, these compounds were able to 
inhibit the production of the signal molecules HHQ and PQS in PA14 pqsH mutant and wt, 
respectively. However, the effects of these QSIs on the other MvfR-related small molecules were 
not studied. Considering that 2-AA, HQNO, and DHQ are pathogenicity-promoting molecules in P. 
aeruginosa infections, it was important to analyze the behavior of the inhibitors on the production of 
all these anthranilic acid derivatives. To ensure a convenient analytic procedure, we developed an 
“all-in-one” method for the simultaneous evaluation of these bacterial metabolites. Following the 
protocol by Lépine and coworkers (Lépine et al., 2003) with some optimizations, a single assay for 
quantification of the relevant pqs-related small molecules was established allowing medium 
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throughput, easy sample processing, low material consumption, without relevant interference 
between analytes. 
 
 
Figure 2 Structures of the compounds evaluated in this work. MvfR antagonist 1, PqsBC inhibitors 3 and 4. 
 
Effects of MvfR antagonists on pqs-related small molecules 
The MvfR antagonists 1 and 2 were able to reduce dose-dependently the production of the alkyl-
quinolones (AQs) and 2-AA in PA14 wt with an IC50 of 1.1 μM and 3.1 μM, respectively (Table 1, 
Figure 3AB). Interestingly, the sigmoidal curves of each of these metabolites were very steep with a 
Hill coefficient over 1 giving the idea of a possible exponential effect of the MvfR natural ligands 
on the pqs regulon expression. Moreover, while DHQ production was inhibited at high 
concentrations, its biosynthesis was enhanced up to 330 % and 396 % after the respective incubation 
of P. aeruginosa with 1 and 2 at a concentration close to the compounds’ IC50s (inhibitor 
concentration causing half maximum inhibition). The basal levels of DHQ were reached at lower 
doses of the two QSIs. Nevertheless, 1 and 2 were able to reduce dose-dependently the overall 
biosynthesis of these metabolites with an IC50 of 1.2 μM and 3.8 μM, respectively. 
 
Table 1 Effects of MvfR antagonists on production of MvfR-related small molecules in PA14 wt. 
Compounds 
2-AA IC50 
[μM] 
Maximal DHQ 
production 
[%] 
HQNO IC50 
[μM] 
HHQ + PQS 
IC50 [μM] 
Overall IC50 
[μM] 
1 
1.3 
(1.1−1.2)a 
330 ± 12
b
 
@ 1 μM 
1.2 
(1.1−1.3)a 
1.1 
(1.0−1.2)a 
1.2 
(1.1−1.3)a 
2 
3.6 
(3.3−3.9)a 
396 ± 25
b
 
@ 3 μM 
3.8 
(3.5−4.0)a 
3.1 
(2.9−3.3)a 
3.8 
(3.6−4.1)a 
a
 95 % Confidence Intervals. 
b
 Standard Error of the Mean intervals. 
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Figure 3 Dose-response curves of MvfR antagonists acting on MvfR-related small molecules production in PA14 
strains. 1 (A) and 2 (B) in PA14 wt. 2-AA: green. DHQ: orange. PQS + HHQ: grey. HQNO: red. Sum of all anthranilic 
acid derivatives: black. 1 (C) and 2 (D) in PA14 pqsH mutant. 2-AA: green. DHQ: orange. HHQ: grey. HQNO: red. 
Sum of all anthranilic acid derivatives: black. The “x” axes indicate the logarithm of the concentration of the antagonists 
in molar units (M). The error bars indicate Standard Error of the Mean. 
These compounds were also evaluated in PA14 pqsH mutant strain, which does not convert HHQ 
into PQS. Notably, in a clinical setting, it has been observed that P. aeruginosa tends to produce 
much more HHQ than the hydroxylated analog (Que et al., 2011) and used as potential biomarker of 
early stage infections (Barr et al., 2016). Our experiments with the PQS-deficient pqsH mutant 
revealed that the QSIs showed similar profiles on the other pqs-related molecules production 
compared to PA14 wt. Indeed, 1 and 2 efficiently inhibited AQs and 2-AA production displaying an 
IC50 of circa 0.30 μM and 0.85 μM, respectively, and very steep inhibitory curves as in PA14 wt 
(Table 2, Figure 3CD). Likewise, they enhanced DHQ formation up to 300 % and 373 % at their 
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respective IC50 concentration. Considering that PQS is more active than HHQ in inducing pqs 
expression (Xiao et al., 2006), it is not surprising that the MvfR antagonists were more potent in 
repressing the biosynthesis of pqs-related signal molecules in PA14 pqsH mutant than in wt.  
 
Table 2 Effects of MvfR antagonists on production of anthranilic acid derivatives in PA14 pqsH 
mutant. 
Compounds 
2-AA IC50 
[μM] 
Maximal DHQ 
production 
[%] 
HQNO IC50 
[μM] 
HHQ IC50 
[μM] 
Overall IC50 
[μM] 
1 
0.19 
(0.16−0.22)a 
304 ± 2
b
 
@ 0.2 μM 
0.27 
(0.25−0.30)a 
0.27 
(0.25−0.30)a 
0.32 
(0.30−0.34)a 
2 
0.69 
(0.59−0.81)a 
373 ± 18
b
 
@ 0.6 μM 
0.73 
(0.67−0.80)a 
0.91 
(0.85−0.96)a 
0.86 
(0.81−0.91)a 
a
 95 % Confidence Intervals. 
b
 Standard Error of the Mean intervals. 
 
The characteristic profiles in wt and pqsH mutant of this class of QSIs, such as the steep inhibitory 
dose-dependent curves and the overproduction of DHQ close to the IC50 for AQ inhibition, suggest 
the pqs autoloop as a reason. Actually, PQS and HHQ have high activity toward MvfR in the 
nanomolar range (Lu et al., 2014b; Xiao et al., 2006) and the actual QS signal is amplified through 
expression of enzymes, which produce again a multitude of additional MvfR natural ligands. 
Antagonizing the transcriptional regulator would thus have a higher-order effect on the downstream 
products resulting from pseudo-cooperative effects. Each decrease in signal molecule synthesis 
achieved by MvfR antagonism would have an additional impact on MvfR deactivation due to less 
competing autoinducers. In the concentration range close to the antagonist IC50, it would be 
plausible that the biosynthetic pathway cannot convert the major amount of anthranilic acid into 
HHQ and PQS maybe because of a slow kinetic step in the biosynthesis. Considering the low 
affinity of 2-ABA toward PqsBC (Drees et al, 2016), it is feasible to claim that the slow step is the 
condensation and cyclization reaction performed by PqsBC. This would lead to an accumulation of 
the reactive intermediate 2-ABA that quickly cyclizes into DHQ. 
For confirming these hypotheses, the compounds were evaluated in PA14 pqsC mutant, which 
synthesizes only 2-AA and DHQ, in an experimental setup with and without exogenous addition of 
the signal molecule PQS. Since these bacteria do not produce any MvfR natural ligands, the pqs 
autoloop is consequently absent and it was possible to control its expression with external 
administration of PQS. Exogenous addition of the quinolone of 1 μM and 10 μM reduced the 
potency of the QSIs on MvfR-related small molecules synthesis of circa one and two orders of 
magnitude, respectively, and increased the steepness of the inhibitory curves (Table 3, Figure 4). 
 
42 
 
 
Figure 4 Dose-response curves of MvfR antagonists acting on 2-AA and DHQ production in PA14 pqsC mutant with 
and without external addition of PQS. Effect of 1 on 2-AA (A), DHQ (B) and 2-AA + DHQ (C) synthesis. Effect of 2 on 
2-AA (D), DHQ (E) and 2-AA + DHQ (F) synthesis. Concentration of PQS: 0 μM (green curves), 1 μM (light blue 
curves), 10 μM (dark blue curves). The “x” axes indicate the logarithm of the concentration of the antagonists in molar 
units (M). The error bars indicate Standard Error of the Mean. 
Actually, the IC50 of 1 on 2-AA production worsened from 50 nM (without PQS) over 0.3 μM (with 
1 μM PQS) to 4.2 μM (with10 μM PQS). In addition, the concentration of compound needed to 
reduce DHQ production to 50 % shifted from 30 nM (without PQS) over 90 nM (1 µM PQS) to 1.7 
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μM (10 μM PQS). Consequently, the overall effect of the QSI on the production of pqs-related 
molecules within the PqsADE biosynthetic pipeline present in the pqsC mutant was also affected by 
PQS administration. Hence, an increase of IC50s from 30 nM (no PQS) over 0.11 μM (1 µM PQS) to 
2.0 μM (10 μM PQS) was observed. In a similar manner, compound 2 showed higher IC50s on 2-AA 
formation revealing an enhancement from 30 nM (without PQS) to 0.49 µM (1 µM PQS) and 4.8 
μM (10 µM PQS). Similarly, the DHQ IC50 increased from 20 nM (without PQS) to 0.23 µM (1 µM 
PQS) and 2.9 μM (10 µM PQS). The IC50 on the total biosynthesis of the MvfR-related molecules 
shifted from 20 nM (without PQS) to 0.27 µM (1 µM PQS) and 3.0 μM (10 µM PQS). 
 
Table 3 Effects of MvfR antagonists on 2-AA and DHQ production in PA14 pqsC mutant with and 
without external addition of PQS. 
Compounds 
Exogenous 
PQS [μM] 
2-AA IC50 
[μM] 
DHQ IC50 
[μM] 
2-AA + DHQ 
IC50 [μM] 
1 
0 
0.05 
(0.04−0.06) 
0.03 
(0.03−0.04) 
0.03 
(0.02−0.04) 
1 
0.33 
(0.28−0.38) 
0.09 
(0.05−0.18) 
0.11 
(0.07−0.19) 
10 
4.2 
(3.0−5.8) 
1.7 
 (1.3−2.3) 
2.0 
 (1.4−2.8) 
2 
0 
0.03 
(0.02−0.05) 
0.02 
(0.01−0.04) 
0.02 
(0.01−0.03) 
1 
0.49 
(0.37−0.65) 
0.23 
(0.17−0.31) 
0.27 
(0.17−0.41) 
10 
4.8 
(4.0−2.9) 
2.9 
(2.4−3.6) 
3.0 
(2.5−3.8) 
The data are reported with 95 % Confidence Interval. 
 
These findings confirmed that the presence of PQS in the bacterial culture plays an important role in 
controlling the biosynthesis of pqs-related molecules. Indeed, when the natural ligand is present, the 
efficiency of the compounds was strongly reduced as the shifts in IC50 confirmed. In addition, the 
increased steepness of the inhibitory curves after addition of PQS to the PA14 pqsC mutant culture 
displayed that, in case of a small reduction in concentration of QSIs, the MvfR-related compounds 
were quickly restored to the basal production level. 
Furthermore, the expression levels of pqsA were monitored under MvfR antagonist treatment using 
the PA14 wt transformed with the plasmid carrying the construct pqsA-GFPASV (Yang et al., 2007). 
The kinetic studies showed that the expression of the plasmidic pqsA promoter occurred in the 
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exponential phase of bacterial growth as for the genomic pqs operon (Déziel et al., 2004) and the 
tested QSIs were highly efficient in reducing it. In detail, 1 and 2 inhibited the expression displaying 
IC50s of 16 nM and 1.5 µM, respectively (Figure 5).  
 
Figure 5 Expression of pqsA-GFPASV (dotted lines) and growth curves (solid lines) of Pseudomonas aeruginosa treated 
with 1 (A) and 2 (B). IC50 curves of 1 (C) and 2 (D). The “x” axes indicate the logarithm of the concentration of the 
antagonists in molar units (M). The error bars indicate Standard Error of the Mean. 
Combining these findings with the results in PA14 wt and pqsH mutant indirectly confirmed that the 
action of autoinducers HHQ and PQS within this positive feedback loop is the explanation for the 
pronounced steepness of the sigmoidal dose-response curves for 2-AA, HHQ, PQS, and HQNO 
levels. The fact that down-regulation of the pqsA operon results in an initial increase in DHQ, while 
the other investigated components show the expected sigmoidal dose-response curves, suggests that 
either 2-ABA-CoA or 2-ABA accumulate in this scenario, which can be spontaneously degraded to 
the shunt product. From published studies on the whole PQS biosynthesis cassette, it can be 
assumed that the reactions mediated by the PqsAD-cascade proceed quickly enough also at lowered 
enzyme concentrations to enable sufficient 2-ABA-CoA production. These initial steps should be 
more dependent on the cellular availability of the substrates anthranilic acid and malonyl-CoA. The 
hydrolysis catalyzed by PqsE can also be performed by housekeeping thioesterases like TesB. But, 
45 
 
an analysis of a pqsE transposon mutant by Drees et al. regarding the profile of PQS-related 
molecules showed increased DHQ levels (Drees, Fetzner, 2015). We corroborated and extended the 
data on this strain with the established pqs-related small molecule quantification method (Figure 6). 
As expected for this strain, 2-AA levels are reduced while DHQ concentration is dramatically 
increased hinting at accumulation of the reactive intermediate 2-ABA-CoA. Finally, insufficient 
action of PqsBC and, thus, accumulation of 2-ABA should lead to both increased DHQ and 2-AA 
levels. 
 
Figure 6 Relative production of 2-AA, DHQ, HQNO, HHQ + PQS and overall amount of AQs in PA14 pqsE mutant 
compared to PA14 wt. The error bars indicate Standard Error of the Mean. 
Hence, the gathered information suggests that through the MvfR-antagonist-induced down-
regulation of the pqsA operon an initial accumulation of 2-ABA-CoA rather than 2-ABA takes place 
(as in the pqsE mutant). Interestingly, it has been shown that the condensation reaction mediated by 
PqsBC should be the rate-limiting step in this biosynthetic cascade (Drees, Fetzner, 2015). Thus, we 
consider it rather surprising that we observe a metabolite profile that hints more towards the role of 
2-ABA-CoA upon partial inactivation of the pqsA operon. 
Nevertheless, at very low levels of MvfR activity, DHQ is finally reduced as the diminished PqsAD 
cascade ceases to operate efficiently resulting in the observed metabolite profiles. 
Among the pqs-related molecules produced by this pathogen, 2-AA was shown to be a key factor for 
switching the infection from acute to chronic state favoring the formation of persister cells 
(Kesarwani et al., 2011; Que et al., 2013). Actually, high levels of this QS compound enhanced the 
genesis of these metabolically inactive bacteria within the population reducing the killing activity of 
antibiotics. Considering the high efficiency of the MvfR antagonists in reducing 2-AA (Starkey et 
al., 2014), these QSIs were evaluated in their capability to modify the survival fraction of the 
pathogen after treatment with meropenem. A dose of 10 µM of 1 and 2 reduced significantly 
persisters development in PA14 wt from 1.2 × 10
-6
 of the untreated control to 2.3 × 10
-7
 and 3.7 × 
10
-7
, respectively, reaching the same levels of the 2-AA non-producing strain PA14 mvfR mutant, 
that is 2.7 × 10
-7
 (Figure 7). These findings corroborated the importance of suppressing the 
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biosynthesis of this carbonyl compound via blockage of the transcriptional regulator for achieving a 
more efficient antibiotic therapy against P. aeruginosa infections. 
 
Figure 7 Persister cells survival of PA14 wt with and without MvfR antagonists and PA14 mvfR mutant after the 
treatment with 10µg/mL of meropenem for 24 h. The error bars indicate 95% Confidence Interval of the geometric 
mean. Statistical analysis performed with non-parametric one-way ANOVA (α = 0.05; **** = p<0.0001; *** = 
p<0.003; * = p<0.05). 
 
Effects of PqsBC inhibitors on mvfR-related small molecules 
The PqsBC inhibitors 3 and 4 reduced the production of the MvfR natural ligands in PA14 wt down 
to 34 % and 35 %, respectively, at their highest concentration (Table 4, Figure 8A). As expected 
(vide supra), the levels of 2-AA and DHQ strongly increased after the treatment with such inhibitors 
up to 188 % and 389 % after incubation with 250 µM of 3 and 415 % and 654 % with 10 µM of 4. 
Surprisingly, the synthesis of HQNO was also enhanced up to two times compared to the untreated 
bacteria. Interestingly, the overall production of the pqs signal molecules was not significantly 
affected. Reducing the concentration of these QSIs led to a reduced inhibitory activity on HHQ and 
PQS production and a relapse of 2-AA, DHQ and HQNO to the respective basal levels. 
The compounds were also evaluated in PA14 pqsH mutant giving similar results obtained with the 
isogenic wt (Table 5, Figure 8B). Here, 3 and 4 reduced at their highest dosage the formation of 
HHQ down to 62% and 73%, respectively. Moreover, the production of 2-AA, DHQ, and HQNO 
was increased by 157 %, 581 %, and 265 % after treatment with 250 µM of 3 and 150 %, 264 %, 
and 141 % after incubation with 10 µM of 4 compared to the untreated control. In addition, as in 
PA14 wt, the overall amount of the MvfR-related compounds was not affected by the addition of 
these QSIs. 
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Figure 8 Effects of PqsBC inhibitors on pqs related signal molecules production in PA14 strains. (A) 3 and 4 in PA14 
wt. 2-AA: green. DHQ: orange. PQS + HHQ: grey. HQNO: red. Sum of all anthranilic acid derivatives: black. (B) 3 and 
4 in PA14 pqsH mutant. 2-AA: green. DHQ: orange. HHQ: grey. HQNO: red. Sum of all anthranilic acid derivatives: 
black. The error bars indicate Standard Error of the Mean. Statistical analysis performed with one-way ANOVA (α = 
0.05).  
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Table 4 Production of pqs signal molecules in PA14 wt after the treatment with PqsBC inhibitors. 
Compounds 
Concentration 
[μM] 
2-AA [%] DHQ [%] HQNO [%] 
HHQ + PQS 
[%] 
Overall [%] 
3 
250 188 ± 4 389 ± 33 198 ± 12 34 ± 1 98 ± 8 
50 152 ± 4 249 ± 15 201 ± 10 57 ± 1 101 ± 5 
10 111  ± 8 141 ± 31 148 ± 19 81 ± 6 100  ± 3 
2 107 ± 2 115 ± 7 128 ± 1 93 ± 4 102 ± 2 
4 
10 415 ± 39 654 ± 49 218 ± 16 35 ± 3 136 ± 5 
1 134 ± 7 131  ± 12 181 ± 39 86 ± 2 100 ± 5 
0.1 99 ± 4 102 ± 1 103 ± 2 96 ± 3 98 ± 3 
0.01 99 ± 4 100 ± 4 97 ± 2 103 ± 5 99 ± 3 
100% is the level of metabolite produced in the untreated PA14 wt. The data are reported with 
Standard Error of the Mean intervals.  
 
Table 5 Production of pqs signal molecules in PA14 pqsH mutant after the treatment with PqsBC 
inhibitors. 
Compounds 
Concentration 
[μM] 
2-AA [%] DHQ [%] HQNO [%] HHQ [%] Overall [%] 
3 
250 157 ± 8 581 ± 76 265 ± 8 62 ± 6 107 ± 4 
50 134 ± 5 355 ± 31 255 ± 10 81 ± 4 108 ± 3 
10 126 ± 6 215 ± 3 199 ± 2 91 ± 4 104  ± 4 
2 102 ± 2 133 ± 2 138 ± 1 97 ± 2 101 ± 2 
4 
10 150 ± 3 264 ± 11 141 ± 1 73 ± 4 92 ± 6 
1 121 ± 2 139  ± 3 143 ± 2 91 ± 1 98 ± 2 
0.1 102 ± 1 102 ± 2 106 ± 1 100 ± 3 100 ± 2 
0.01 99 ± 1 99 ± 1 99 ± 1 95 ± 1 95 ± 1 
100% is the level of metabolite produced in the untreated PA14 pqsH mutant. The data are reported 
with Standard Error of the Mean intervals. 
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Additionally, 3 and 4 were examined in PA14 pqsC mutant for confirming their target selectivity. 
Both compounds turned out to be inactive in reducing 2-AA and DHQ production independently 
from the concentration of PQS added into the culture (Figure 9) supporting the in vitro 
characterization of the two inhibitors (unpublished results; Starkey et al., 2014). 
Considering their efficiency in reducing the production of the MvfR natural ligands in PA14 wt and 
pqsH mutant, these inhibitors were analyzed in the pqsA-GFPASV construct for monitoring their 
potential ability for reducing the expression of the pqs operon. Actually, 3 and 4 reduced the operon 
transcription down to 36 % and 15 %, respectively, at their highest dosage (Figure 10). 
 
Figure 9 Effects of PqsBC inhibitors on 2-AA and DHQ production in PA14 pqsC mutant. (A) 3 and (B) 4. 2-AA: 
green. DHQ: orange. Sum of all anthranilic acid derivatives: black. The error bars indicate Standard Error of the Mean. 
Statistical analysis performed with one-way ANOVA (α = 0.05). 
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Figure 10 Expression of pqsA-GFPASV (dotted lines) and growth curves (solid lines) of Pseudomonas aeruginosa 
treated with 3 (A) and 4 (B). (C) Percentage of pqsA-GFPASV expression after PqsBC inhibitors addition. The error bars 
indicate Standard Error of the Mean. Statistical analysis performed with one-way ANOVA (α = 0.05; **** = p<0.0001). 
Taking into consideration the obtained results, the effects of the PqsBC inhibitors on the MvfR 
natural ligands, 2-AA, and DHQ production fitted to the expected behavior of blocking the hetero-
dimer PqsBC. Actually, its inhibition would lead to a reduced conversion of the reactive 2-ABA into 
HHQ with consequently reduced expression of the pqs operon. The excess of this intermediate 
would be consequently transformed more into the stable molecules 2-AA and DHQ, conversions 
that do not require PqsBC. According to the current model of HQNO synthesis, 2-ABA is N-
oxidized by the oxidase PqsL into its hydroxylamine form, 2-HABA. We assume that this moiety of 
the intermediate should be a more reactive nucleophile (Ningst et al., 2012) than the amine of 2-
ABA or a better substrate and that, consequently, the reaction of condensation and cyclization 
performed by the hetero-dimer proceeds faster. Moreover, it is plausible to expect that the enzyme 
complex has a different affinity towards the amine and the hydroxylamine intermediates and, due to 
this fact, the inhibitors would have also different activities in blocking both reactions. Based on the 
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obtained results, this hypothesis would reasonably explain the overproduction of HQNO after 
incubation of PA14 with PqsBC inhibitors. But, we do not exclude that an additional, yet unknown 
bypass reaction towards HQNO might cause this unexpected observation. In addition, the analysis of 
the overall amount of the pqs-related small molecules revealed that these QSIs modify only the ratio 
of the QS compounds without affecting the total content. 
Because of the different QS profiles of PqsBC inhibitors compared to MvfR antagonists and, in 
particular, the inductive effects on 2-AA production, 3 and 4 were examined regarding their 
capability to affect persister cells development. We found that only 3 significantly enhanced the 
persistence phenotype of PA14 wt increasing the survival fraction from 1.2 × 10
-6
 (untreated) up to 
4.6 × 10
-6
 cells. This corresponds to the levels of PA14 wt treated with 2-AA as well as the untreated 
PA14 pqsBC mutant showing persister rates of 7.2 × 10
-6
 and 4.1× 10
-6
, respectively (Figure 11). 
These findings confirmed that targeting PqsBC led to an enhanced survival of the bacteria. This 
might ultimately result in a reduced efficiency of antibiotic therapy. 
 
Figure 11 Persister cells survival of PA14 wt with and without PqsBC inhibitors or 2-AA and PA14 pqsBC mutant after 
the treatment with 10µg/mL of meropenem for 24 h. The error bars indicate 95% Confidence Interval of the geometric 
mean. Statistical analysis performed with non-parametric one-way ANOVA (α = 0.05; *** = p<0.003; ** = p<0.01; * = 
p<0.05). 
 
Conclusions 
The profiling of Pseudomonas aeruginosa MvfR antagonists and PqsBC inhibitors emphasized the 
importance in selecting the target for the development of new anti-infectives. The analysis of the 
pqs-related small molecules after the incubation of PA14 strains with MvfR antagonists showed the 
high efficiency of these QSIs at the highest concentration to strongly reduce the formation of the 
bacterial metabolites. However, the treatment of the bacteria at lower concentration of MvfR 
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antagonists revealed a characteristic profile featuring an overproduction of DHQ at concentrations 
close to the compounds’ IC50. The PqsBC inhibitors showed to be less efficient in reducing the 
MvfR natural ligands synthesis at the highest dosages and, moreover, lead to an increased 
production of 2-AA, DHQ, and HQNO. Actually, they mainly affected the ratio of QS molecules 
generated within a bacterial population without modifying the overall production. Finally, we could 
corroborate the importance of reducing 2-AA production through MvfR antagonism for achieving 
lower persistence and, consequently, more efficient antibiotic therapy. In the end, we recommend 
that the preferable target for blocking the pqs system is the transcriptional regulator MvfR. In case 
of PqsBC inhibitors, a combination with other QSIs (e.g., MvfR antagonists) might still be a valid 
route towards novel anti-infectives. 
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10 DISCUSSION 
10.1 Development of PqsD inhibitors 
One of the main goals of the thesis was to develop and optimize inhibitors against the 
enzyme PqsD because of its key role in the pqs-related signal molecules biosynthesis. Two 
strategies were applied: a ligand-based and a similarity-guided approach. 
 
10.1.1 Ligand-based approach 
Based on the results of Storz and coworkers (Storz et al., 2012), the PqsD inhibitor I was 
identified simplifying and rigidifying the scaffold of the tetrahedral intermediate of A-CoA in the 
catalytic pocket of the enzyme. Considering the potential noxious effects of the nitro group 
(Kovacic, Somanathan, 2014), it was attempted to exchange it with other electron withdrawing 
groups (EWGs) as trifluoromethyl, nitril and halogens. However, all these derivatives revealed to be 
completely inactive in the PqsD cell-free assay highlighting the importance of the nitro group in the 
enzyme inhibition. Consequently, compound I was evaluated in toxicity and mutagenesis assays 
using respectively human THP-1 macrophages and Salmonella typhimurium (Ames test). These tests 
revealed that this QSI did not show neither toxic nor mutagenic effects. Consequently, the 
optimization of the scaffold was attempted for improving the activity of the compound class both in 
vitro and in cellulo assays. Around 50 compounds were designed and synthesized as fully described 
in the publication A changing the substitution pattern on the nitrophenyl and the R substituents (Fig. 
5). 
 
Fig. 5 Molecular scaffold of the (2-nitrophenyl)methanol compounds. G could be EWG, or EDG, or H. R could be alkyl 
chains, or (hetero)aromatic rings, or alkyl chain with terminal amine or phthalimide moiety, or H. 
Compound I was shown to bind tightly the bacterial enzyme in its active site with a slow 
onset kinetic and displaying, as a consequence, a higher potency in case of longer pre-incubation 
time with PqsD (Storz et al., 2013). Consequently, the potency of the compounds was evaluated 
quantifying the concentration of inhibitor necessary for blocking the 50% of conversion (IC50) of A-
CoA into HHQ using different pre-incubation times (10 and 30 minutes) of the enzyme with the 
QSIs (Storz et al., 2012; Storz et al., 2013). Actually, compound I showed an IC50 of 3.2 ± 0.1 μM 
using 10 min pre-incubation protocol and an IC50 of 0.5 ± 0.1 μM after 30 min incubation with 
PqsD. So, I was taken as reference compound for studying the SAR of this QSI class. The different 
properties of the substituents added in position 4 and 5 on the nitrophenyl ring affected interestingly 
the compound behavior. The analysis of the inhibitors with the short pre-incubation protocol 
revealed that while the addition of EWGs, as chlorine or nitro, diminished activity compared to I, 
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the analogues having electron donating groups (EDGs), as methyl or methoxy groups, resulted to be 
as potent as I. Furthermore, the comparison of the results between short and long pre-incubation 
time assay revealed that substituents in position 4 can modulate the binding kinetics. Actually, while 
EWGs slowed down the onset of the compound, the EDGs accelerated it. On the contrary, 
substituents in 5 did not modify the kinetic onset. Dealing with a slow tight binder would be 
beneficial, as it would imply a longer residency of the inhibitor in the enzyme and, consequently, a 
more efficient blockage of the protein functionality. So, the nitrophenyl ring was not additionally 
substituted and the scaffold optimization was continued on the R side. The phenyl in R of I was 
replaced with alkyl chains and saturated rings of different size and molecular volume. PqsD 
inhibition analysis revealed that compounds with bulky and/or long aliphatic moieties showed lower 
potency than the QSIs with smaller linear chains. It is plausible that big substituents have steric 
clashes and need high entropic penalties for binding PqsD. Considering the positive effect of short 
alkyl chains in inhibiting PqsD, R was replaced with short saturate linkers bearing at the end 
functional groups, as phenyl ring, amine, phthalimide and fluorophores. Only the phthalimide 
derivatives resulted to be as potent as I showing IC50s in the high nanomolar range with the longer 
pre-incubation time as compound II which displayed an IC50 of 0.3 ± 0.1 μM. The compounds with 
an amino moiety at the end of an alkenyl chain were inactive or weakly active as expected. Actually, 
it is plausible that at physiological pH the amino group is protonated and, consequently, an 
electrostatic repulsion occurs between the compound and the positively charged entrance channel. 
The derivatives carrying phenyl rings and fluorophores showed to have acceptable IC50s in the 
single digit micromolar range, but still less potent than I maybe due to steric clashes and/or entropic 
penalties. Furthermore, the phenyl group present in I at R was exchanged with several 
heteroaromatic rings. While compounds with thiophene and pyridine did not show a better 
inhibitory activity on PqsD compared to I, the derivatives with furan displayed a particular behavior. 
Actually, the 2-furyl VI derivative showed to be as potent as I; on the contrary, the 3-furyl analogue 
VII was almost inactive. A deep analysis of this specific compound revealed that it is a selective 
PqsBC inhibitor (unpublished data) (Table1). 
The most in vitro active QSIs were, then, tested in bacterial cultures of P. a. pqsH mutant 
capable to produce all the biosynthetic products of the pqs system down to HHQ with the exception 
of PQS. Consequently, it was monitored the reduction of HHQ after overnight incubation of PqsD 
inhibitors with the bacteria. The compounds were evaluated at a final concentration of 250 μM, if 
soluble. Considering that I inhibited HHQ production of 43 ± 4%, the compounds having additional 
substituents on the nitrophenyl ring resulted to be less active or completely inactive. On the other 
side, modification of R moiety affected the activity of the compounds in the cell based assay 
depending on its chemical properties. The QSIs having alkyl chains showed a particular profile. 
Starting from the hydrogen derivative, the compounds displayed increasing activity up to the ethyl 
analogue III capable to reduce HHQ of 61 ± 2%. Then, the enlargement of R reduced the cellular 
potency of the analogues. Furthermore, all the PqsD inhibitors characterized by having a saturated 
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linker bearing specific functional groups were completely inactive. The introduction of 
heteroaromatic rings on R, on the contrary, led to the identification of the most potent QSIs of the 
class in the cellular settings capable (Table 1).  
 
Table 1 Most potent compounds of the class in cell-free and/or whole-cell assays using PA14 pqsH 
mutant. 
 
Compound R 
IC50 [µM]  
(10 min preinc.) 
a
 
IC50 [µM]  
(30 min preinc.) 
b
 
% HHQ inhibition in 
PA14 pqsH mutant 
I Ph 3.2 ± 0.1 0.5 ± 0.1 43 ± 6 
c
 
II (CH2)2Phth 1.2 ± 0.1 0.3 ± 0.1 Inactive 
d
 
III Et 1.1 ± 0.2 0.8 ± 0.1 61 ± 2 
c
 
IV 2-Thienyl 14.3 ± 1.9 1.5 ± 0.2 64 ± 6 
c
 
V 3-Thienyl 5.9 ± 0.9 6.4 ± 1.9 74 ± 6 
c
 
VI 2-Furyl 1.8 ± 0.4 0.9 ± 0.1 51 ± 15 
c
 
VII 3-Furyl 28 % @ 50 µM 13.1 ± 2.8 73 ± 2 
c
 
Errors indicate Standard Deviation. a Cell-free PqsD assay with 10 minutes pre-incubation protocol of enzyme with compound. b Cell-
free PqsD assay with 30 minutes pre-incubation protocol of enzyme with compound. c Compounds tested at 250 µM. d Compounds 
tested at 125 µM. 
 
A comparison of the results between in vitro and in cellulo assays revealed that there was not 
a clear correlation of the activities between the two protocols. Actually, only few compounds that 
were highly active in the PqsD assay efficiently reduced also HHQ production in P. a. cultures as I, 
III and VI. A deeper analysis of the compounds properties disclosed that most of the inhibitors 
active in the cellular setting have a molecular weight below 250 Da, a cut off value much smaller 
compared to the one reported for Gram-negative active drugs of 600 Da (O'Shea, Moser, 2008). This 
finding highlighted the characteristic low permeability of the membranes of this class of bacteria, 
especially of the outer layer which is rich in proteins involved in transporting compounds inside and 
outside the cell (Nikaido, 2003). So, it should not be excluded that these QSIs require transporters or 
porins for entering into the cells, or are expelled by the bacterium through the usage efflux pumps. 
In addition, P. a. expresses also some enzymes for xenobiotic metabolization as nitroreductases, 
needed for the reduction of the nitro to an amino group, and acetylases, necessary for the 
conjugation of acetyl moieties (Noguera, Freedman, 1996; Schackmann, Müller, 1991). 
Consequently, the requirement of high concentrations of compounds could be also due to their 
possible inactivation by proteins involved in xenobiotic metabolism. 
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10.1.2 Similarity-guided approach 
Taking into consideration functional and mechanistic properties, PqsD has some common 
features with the Poliketide Synthase (PKS) family and, in particular, with the Chalcone Synthase 
(CHS2), a vegetable protein expressed by Medicago sativa (known also as alfalfa) (Bera et al., 
2009; Ferrer et al., 1999). CHS2, as PqsD, is a condensing enzyme and it favors the conversion of p-
coumaric acid into the flavone naringenin employing three molecules of M-CoA (Ferrer et al., 1999) 
(Fig. 6). In addition, the vegetable protein can catalyze in unnatural condition the conversion of 
other compounds belonging to cinnamic acid family, as caffeic acid, cinnamic acid and ferulic acid, 
into the respective flavones (Dao et al., 2011; Schröder, 2000). 
 
Fig. 6 Conversion of p-coumaric acid into naringenin by CHS2 
Even if CHS2 and PqsD are not homologues, the enzymes share several characteristics. 
Firstly, both proteins employ the triad cysteine-histidine-asparagine for their condensation reactions. 
Moreover, maybe due to the use of the same secondary substrate M-CoA, CHS2 and PqsD have 
similar active site volume, comparable deepness of the CoA binding pocket and the entrance of the 
catalytic site is surrounded by basic aminoacids (Bera et al., 2009; Ferrer et al., 1999; Dao et al., 
2011). Encouraged by the positive results obtained in the application of a similarity-guided approach 
between the bacterial enzymes PqsD and FabH for the development of new QSIs (Weidel et al., 
2013), a similar strategy was employed with CHS2 and the P. a. protein. Starting from the scaffold 
of the CHS2 substrates, more than 30 compounds were designed and synthesized as fully described 
in the publication B. 
The evaluation of the cinnamic acids analogues and their respective methyl esters in the 
PqsD cell-free assay revealed that only the methyl caffeate (VIII) showed a significant inhibition of 
the enzymatic conversion with an IC50 = 51 ± 4 μM. However, this compound contains an α,β-
unsaturated system that could act as Michael-acceptor. Consequently, it might react with 
nucleophiles in the cell and display toxic effects (Mulliner et al., 2011). So, the olefinic linker was 
exchanged with a saturated congener as in compound IX which resulted to be much more potent 
exhibiting an IC50 = 23 ± 1 μM. The next step of scaffold optimization involved the modification of 
different moieties of the molecule, as the substitution pattern on the phenyl ring, the carboxylic part 
and the linker (Fig. 7). 
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Fig. 7 Molecular scaffold of the CHS2 substrate-like compounds. G1 and G2 could be substituents with different 
chemical properties, or H. R could be esters or amide bearing hydrocarbon moieties of different size. 
Actually, the replacement of the catechol with any other substituents, as nitro, acetal and the 
isosters amino, fluorine and methyl, provoked a completely loss in activity highlighting the 
fundamental requirement of the 3,4-dihydroxy group for having PqsD inhibition. Consequently, this 
feature was kept and modification on the carboxylic moiety were attempted for improving activity. 
The introduction of bigger ester substituents from methyl to benzyl (IX−XII) enhanced compound 
potency in relation to the size of the group down to single digit micromolar IC50s as for XI and XII 
(Table 2) suggesting that a favorable hydrophobic interaction could take place between the inhibitor 
and the enzyme. In addition, replacement of the ester with the isoster amide in XIII did not improve 
compound potency. The next step of scaffold optimization involved the linker length. The analysis 
of analogues having different bridge size revealed that longer alkenyl chain improved compound 
activity as the propylene congener XIV showing an IC50 = 7.9 ± 0.2 μM (Table 2). Actually, it is 
plausible that, as for the ester substituents, a favorable hydrophobic interaction is established 
between the QSI and the protein that would counter balance the higher entropic penalty due to the 
longer alkenyl chain. 
Furthermore, the binding mode of this PqsD inhibitor class was analyzed by SPR monitoring 
the association and dissociation sensograms of the compounds on the enzyme (Weidel et al., 2013). 
Actually, the experiment was constituted by two phases. In the first step it was measured the binding 
of compounds on free protein. Then, after washing PqsD with running buffer for removing the 
ligands, the second step consisted in pre-incubating the enzyme with A-CoA followed by addition of 
the inhibitor. Taking into consideration that the pre-treatment with A-CoA blocks the active site, the 
binders can interact with PqsD only in the entrance channel (Fig. 8).  
 
Fig. 8 Representative schemes of the two possible binding mode of inhibitors on PqsD. 1 is a competitor of A-CoA in 
the active site, 2 is an inhibitor that bind the channel before the active site. Case I: PqsD with the compounds. Case II: 
PqsD, preincubated with A-CoA (“A”), with the inhibitors. 
Among the several analogues, six compounds were selected for binding mode evaluation, 
three having the unsaturated linker as VIII and three with the saturated chain as XII. Actually, the 
analysis revealed that these inhibitors are capable to interact with PqsD also after A-CoA treatment 
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and, consequently, they do not bind the enzyme in the catalytic pocket, but likely in the entrance 
channel. 
Furthermore, it was investigated the capability of these pathoblockers to reduce HHQ 
production in PA14 pqsH mutant. As for the (2-nitrophenyl)methanol derivatives, the inhibitors 
were tested at 250 µM. Interestingly, the most potent compounds in the cell-free assay XI, XII, XIV 
revealed to be weakly active or completely inactive in the cell-based test, while the unsaturated 
derivative VIII showed to be the most active inhibitor of the class capable to reduce HHQ 
production of 31 ± 2% at 250 µM (Table 2). In addition, while the amide XIII was as potent as the 
analogue ester in the PqsD cell-free assay, in the cell-based is showed no effect on HHQ reduction. 
 
Table 2 Most potent compounds of the class in cell-free and/or whole-cell assays using PA14 pqsH 
mutant. 
 
Compound Linker R 
IC50 [µM]  
(10 min preinc.) 
a
 
% HHQ inhibition in 
PA14 pqsH mutant 
b
 
VIII CH=CH (E) OMe 51 ± 4 31 ± 2 
IX CH2CH2 OMe 23 ± 1 17 ± 1 
X CH2CH2 OEt 14 ± 1 17 ± 1 
XI CH2CH2 OiPr 8.6 ± 0.6 16 ± 1 
XII CH2CH2 OCH2Ph 5.9 ± 1.2 Inactive 
XIII CH2CH2 NHMe 20 ± 4 Inactive 
XIV CH2CH2CH2 OMe 7.9 ± 0.2 18 ± 2 
Errors indicate Standard Deviation. a Cell-free PqsD assay with 10 minutes pre-incubation protocol of enzyme with compound. b 
Compounds tested at 250 µM. 
 
As for the (2-nitrophenyl)methanol QSIs, also these PqsD inhibitors showed to be efficient in 
reducing the enzymatic catalysis in in vitro settings and active in cellulo only at high concentrations 
without finding a clear correlation between the two assay conditions. Actually, the accessibility of 
the compounds to reach the bacterial target could be challenging due to the low permeability of the 
bacterial membranes as previously mentioned (Nikaido, 2003) and/or due to possible metabolization 
of the QSIs by bacterial esterases (Pesaresi el al., 2005). 
 
10.1.3 Common characteristics of the two classes 
Even if the two approaches applied for the development of PqsD inhibitors were different 
and ended with the discovery of two completely diverse scaffolds, the two compound classes shares 
two main characteristics. Firstly, no correlation was found between high potency in cell-free and in 
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whole-cell assays in both classes. Secondly, high concentration of PqsD inhibitor, such as 250 μM, 
was required for displaying a significant inhibition of the signal molecule. As previously mentioned, 
P. a. is known to have very selective low permeable cellular membranes, thanks also to high 
expression of efflux pumps, and a set of enzymes that can metabolize xenobiotics. However, it 
should not be excluded that targeting PqsD could not completely suppress the pqs system as, for 
example, the partial reduction of HHQ did not affect the production of the redox toxin pyocyanin 
(unpublished data). Consequently, it might be possible that other strategies for blocking this QS 
system should be taken into consideration. 
 
 
10.2 Evaluation of PqsBC inhibitors and MvfR antagonists 
Considering the high doses necessary for reducing HHQ production in P. a. cultures and the 
possibility that PqsD would not be the best target for blocking the pqs system, no further 
optimizations were made on the developed inhibitors. Consequently, a deeper study in the scientific 
literature highlighted the importance of PqsBC and MvfR in coordinating the functionality of this 
QS system, as AQs biosynthesis and P. a. virulence. So, four tool compounds, such as the two 
PqsBC inhibitors VII (unpublished data) and XV (Starkey et al., 2014), and the two most potent 
MvfR antagonists XVI (Starkey et al., 2014) and XVII (Zender et al., unpublished data) (Fig. 9) 
were used for investigating the pqs biosynthetic machinery in different P. a. strains as fully 
described in the manuscript C. 
 
Fig. 9 Structures of the PqsBC inhibitors VII and XV and of the MvfR antagonist XVI. The chemical formula of XVII 
cannot be disclosed because of patent submission on going. 
While it was previously described the activity of these compounds in reducing PQS and 
HHQ production in PA14 wt and its isogenic pqsH mutant, respectively, the effects of these QSIs on 
2-AA, DHQ and HQNO were not elucidated. Consequently, an "all-in-one" assay using the HPLC-
MS/MS was established for detecting the five major pqs-related small molecules in multiple P. a. 
strains modifying the published protocol of Lépine and coworkers (Lépine et al., 2003). The two 
classes of inhibitors showed a characteristic profile regarding mvfr-related small molecule formation 
in PA14 wt and its isogenic pqsH mutant.  
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10.2.1 Effects of MvfR antagonists on pqs-small molecules 
The MvfR antagonists XVI and XVII were capable to completely suppress the overall 
biosynthesis at the highest concentration in both strains. Reduction of the QSI dose provoked a 
quick restoration of the synthesis of AQs and 2-AA as highlighted by the observed very steep 
curves. Furthermore, while XVI and XVII showed respective AQs IC50 of 1.2 μM and 3.8 μM in 
PA14 wt, the compounds were around one order of magnitude more potent in PA14 pqsH mutant 
displaying AQs IC50 of 0.30 μM and 0.85 μM. Actually, this difference in activities between the two 
strains was expected as PQS is much more potent than HHQ in activating the transcriptional 
regulator (Xiao et al., 2006a). Interestingly, the DHQ level tremendously increased at dosages of 
antagonist close to the 2-AA and AQs IC50s for returning to basal levels at lower amounts of 
compound. These overall specific profiles suggested that the pqs autoloop could be one of the 
causing factors. Actually, MvfR antagonization would result in reduced pqs expression with 
subsequent lower amount of signal molecules capable to compete with the QSIs on the 
transcriptional regulator. This would have, in the end, a pseudo-positive cooperative effect on the 
MvfR antagonist efficacy. Furthermore, at concentrations of pathoblocker close to AQs IC50s, the 
biosynthetic machinery would not be capable to convert the major amount of anthranilic acid into 
HHQ/PQS maybe because of slow kinetic step in it. Considering the low affinity of 2-ABA toward 
PqsBC (Drees et al., 2016), it was assumed that the conversion of 2-ABA into HHQ was the slow 
step. Consequently, this would lead accumulation of the reactive intermediate which spontaneously 
cyclize in the stable molecule DHQ.  
So, the compounds were evaluated in PA14 pqsC mutant with and without exogenous 
addition of PQS for modulating operon expression. Actually, XVI and XVII showed smooth 
inhibitory curves of 2-AA and DHQ in absence of signal molecule and IC50s values in the two digits 
nanomolar range. The addition of quinolone increased both the steepness of the curves, and their 
respective IC50s values up to the single digit micromolar range, similar to their inhibitory activity in 
wt strain. These results, consequently, confirmed that PQS and its autoloop would be two factors of 
the steepness of the inhibitory curves. Furthermore, analysis of pqsA expression after addition of 
MvfR antagonist revealed that these QSIs efficiently suppressed the transcription of the operon. 
In addition, the profiling of the pqs-small molecules in PA14 pqsE mutant uncovered a 
profile characterized by a much higher levels of DHQ and lower production of 2-AA and HQNO 
compared to the isogenic wt. This specific distribution of mvfR-related compounds in pqsE mutant 
occurred because the thioester cleavage of 2-ABA-CoA into 2-ABA would be carried out by the 
slow unspecific thioesterase TesB (Drees, Fetzner, 2015). Considering the similar distribution of 2-
AA, DHQ and HQNO between PA14 pqsE mutant and PA14 wt with AQs IC50 doses of antagonist, 
it is plausible that an accumulation of the intermediate 2-ABA-CoA took place in PA14 wt instead 
of the hypothesized 2-ABA.  
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10.2.2 Effects of PqsBC inhibitors on pqs-small molecules 
The analysis of the PqsBC inhibitors VII and XV on pqs-small molecule production in PA14 
wt and pqsH mutant showed that these QSIs were not able to affect the overall formation of QS 
molecules. Actually, these QSIs mainly influenced the distribution of the pqs biosynthetic products 
favoring the increase of 2-AA, DHQ and HQNO amounts and the decrease of signal molecules 
levels. While the increase in 2-AA and DHQ was expected, the higher production of HQNO was 
surprising as the biosynthesis of this specific AQ requires the hetero-dimeric protein.  
Consequently, it was preferable to confirm their target selectivity. So, these QSIs were 
evaluated in PA14 pqsC mutant in which they resulted to be completely inactive. Furthermore, 
analysis of the pqsA expression showed that 500 μM of VII and 10 μM of XV strongly suppressed 
the transcription of the operon in accordance with the efficient reduction of signal molecules at 
similar concentrations. 
Taking into consideration the obtained results and the biosynthetic pathway, it is plausible to 
assume that PqsBC might have different kinetic parameters and affinities depending on the substrate 
to be used, 2-HABA for HQNO and 2-ABA for HHQ. Consequently, the designed PqsBC inhibitors 
would have different inhibitory activity depending on the reaction to be blocked. So, while the 
formation of the signal molecule is inhibited, the reactive intermediate 2-ABA is transformed into 
DHQ, 2-AA and 2-HABA which is, finally, converted into HQNO. 
 
10.2.3 Effects of MvfR antagonists and PqsBC inhibitors on antibiotic tolerance 
Considering the important role of 2-AA in antibiotic tolerance development, the four 
compounds were analyzed to assess their capability to influence the rate of persister cells and, 
consequently, modulate the killing rate of the employed antibiotic meropenem. Actually, the 
efficiency of the MvfR antagonists in reducing the 2-AA formation translated into their capability to 
reduced PA14 wt tolerance to the isogenic mvfR mutant levels with the consequent improvement of 
antibiotic efficacy. On the contrary, while both PqsBC inhibitors enhanced 2-AA production, only 
VII increased persistence to similar levels of PA14 wt incubated with 2-AA. A comparable result 
was obtained for the isogenic pqsBC mutant which led to a reduced antibacterial potency of 
meropenem. 
 
10.2.4 Comparison between PqsBC inhibitors and MvfR antagonists 
The combination of the findings from the pqs-small molecules profiling and persistence 
assessment revealed that targeting PqsBC would not be beneficial for blocking P. a. infections. 
Actually, higher production of 2-AA and HQNO in the infection site would be translated into higher 
chances to develop chronic infections characterized by biofilms richer in persistent cells. In addition, 
the overproduction of DHQ would lead to intoxication of the host cells. Consequently, the 
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eukaryotic cell growth would be inhibited and the mechanism of tissue repair would be strongly 
delayed. 
On the contrary, targeting MvfR would efficiently inhibit the whole pqs system and, 
consequently, reduce P. a. pathogenicity and development of long-term infections. So, the 
employment of the transcriptional regulator antagonists would, firstly, help the host immune system 
in blocking the colonization and invasion of the pathogen in the tissues and, secondly, improve the 
efficacy of antibacterial drugs.  
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11 CONCLUSIONS AND OULOOKS 
 
The evaluation of three different QSI groups, such as PqsD and PqsBC inhibitors and MvfR 
antagonists, helped in understanding more in depth the pqs system and the therapeutic efficiency in 
blocking singularly the proteins. 
The application of two different strategies used in drug discovery, as the ligand-based and 
similarity-guided, helped in the development of PqsD inhibitors based on two diverse scaffolds. 
Deep SAR studies were conducted on both classes which resulted in the identification of potent 
compounds in cell-free settings with IC50s values between single digit micromolar - high nanomolar 
range. In addition, while the (2-nitrophenyl)methanols were shown to bind the enzyme in its 
catalytic site, the catechols revealed to likely interact in the entrance channel of the protein. The in 
cellulo evaluation of the QSIs showed that some compounds potent in the PqsD assay were capable 
to efficiently reduce signal molecule production at 250 μM. However, the usage of such high doses 
in the whole-cell assays suggested three possible explanations. Firstly, it could not be excluded that 
both compound classes were not be able to permeate easily through the bacterial membranes due to 
low import in the cell or high expulsion carried out by efflux pumps. Consequently, in a next step, 
the permeability of the QSIs could be analyzed as employing in vitro models mimicking the 
physicochemical properties of the bacterial membrane (Graef et al., 2016). In case the compounds 
diffuse easily through the bacterial membrane, the PqsD inhibitors could be evaluated in strains 
lacking in the expulsion systems (El'Garch et al., 2007) or tested in combination with efflux pumps 
inhibitors (Lomovskaya et al., 2001). Secondly, based on the arsenal of metabolizing enzymes 
expressed, P. a. may transform the QSIs into inactive forms. So, their possible metabolic 
inactivation could be analyzed through quantification of the inhibitor during cellular incubation by 
HPLC-MS/MS (Said et al., 2016; Bhat et al., 2013).Thirdly, considering the high activity of the 
signal molecules in activating the pqs operon, it might be that PqsD inhibition does not fully 
suppress the expression of the gene cluster. Consequently, analysis of pqs operon expression could 
help such elucidation. 
So, the evaluation of other targets was accomplished, such as the biosynthetic enzyme 
PqsBC and the transcriptional regulator MvfR. After the development of an "all-in-one" HPLC-
MS/MS assays, an extended analysis of all the pqs biosynthetic products was performed using two 
tool compounds for each target protein. PqsBC inhibitors revealed that they mainly affected the 
distribution of the mvfR-related small molecules, but not the overall production. Actually, these 
compounds induced higher 2-AA, DHQ and HQNO biosynthesis, key molecules in persistence, host 
toxicity and biofilm formation, while reduced signal molecules levels. Consequently, the developed 
inhibitors of this heterodimeric protein would not block all its reactions, but only conversion of 2-
ABA into HHQ. On the contrary, the designed MvfR antagonists showed to reduce 2-AA, AQs and 
the overall production dose-dependently with very steep inhibitory curves. In addition, they induced 
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a boost of DHQ formation at AQs IC50 values. Comparing the activities of the compounds in the 
pqsC mutant with and without exogenous PQS, used for modulating operon expression, highlighted 
that the signal molecule and its autoloop are factors which influence the steepness of the curves. 
Furthermore, the similar distribution of the pqs-small molecules between the pqsE mutant and the wt 
with AQs IC50 concentration of antagonist highlighted that the overproduction of DHQ could be due 
to the accumulation of the reactive intermediate 2-ABA-CoA. In addition, considering the different 
effects of the two QSI groups on 2-AA production, their activities in modulating persistence was 
evaluated. While PqsBC inhibitors enhanced bacterial tolerance, MvfR antagonists efficiently 
reduced it displaying, in the end, the preferable profile. 
In the end, this study highlighted that, among the three targets evaluated, blocking MvfR was 
identified as the optimal strategy to be applied for reducing P. a. pathogenicity. Consequently, 
further efforts should be put in the optimization of the known class of compounds designed to 
antagonize the transcriptional regulator and in the discovery of novel scaffolds. In addition, while a 
monotherapy with the studied PqsD or PqsBC inhibitors would not be ideal for treating P. a. 
infections, these compounds could be employed in combination therapies with MvfR antagonists for 
improving the anti-virulence effects of the transcriptional regulator blockers (Thomann et al., 2016). 
Consequently, analysis of pqs-small molecules production and persistence assessments would be 
recommended to be performed after the incubation of P. a. with the combination therapy. Actually, 
these studies will give further information about the efficiency of this therapeutic approach in 
reducing bacterial virulence, and guide the scientific community in how to improve it. 
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